NHS vs private weight-loss treatment: what it costs

Two very different price tags for the same pen

The same licensed medicine — Wegovy or Mounjaro — costs an NHS patient in England the standard prescription charge per item, and a private patient somewhere in the low-to-mid hundreds of pounds each month. That gap makes the NHS route look like the obvious answer, and for people who qualify and can access it, it usually is. But the comparison has more moving parts than two numbers.

The NHS side: low cost, gated access

NHS treatment is funded, so your direct cost is the prescription charge in England (currently under £10 per item) and nothing in the devolved nations. What you spend instead is time and eligibility. Access runs through NICE criteria and, in much of the country, specialist services with substantial waiting lists; Mounjaro's wider primary-care rollout is deliberately phased, starting with the highest clinical need. Our guide to who qualifies on the NHS covers the detail — the short version is that qualifying and being treated soon are different things.

NHS treatment also comes with structure that is easy to undervalue: multidisciplinary support in specialist services, defined review points, and integration with your wider NHS record.

The private side: monthly fees, faster and broader access

Private treatment through a regulated pharmacy typically costs between about £130 and £250 a month depending on the medicine, your current dose (higher doses cost more) and what the provider bundles — consultations, follow-up, delivery. Over a year of treatment that is a four-figure commitment, and honest budgeting should assume the maintenance-dose price, not the starting offer. Our price-variation guide explains how to compare providers fairly.

What the money buys is access: no waiting list, treatment where local NHS provision is thin, and licence-based eligibility that includes people outside current NHS cohorts — for example a BMI of 30 with a single weight-related condition, where a clinician judges treatment appropriate. It also buys choice of format, including the newly approved tablet Foundayo once stocked.

Costs people forget on both sides

On the NHS side: the cost of waiting, which for many people means months of a health problem compounding — and, for some, private interim treatment anyway. On the private side: consultation or review fees where unbundled, delivery charges, and the discipline to stop paying for treatment that is not working rather than drifting on a subscription. On both sides: treatment works alongside diet and activity changes, and stopping treatment without a maintenance plan tends to see weight return — so the realistic budget horizon is longer than a trial month.

A worked comparison over twelve months

Put the two routes side by side over a year, assuming eligibility for both. NHS: prescription charges only (or nothing outside England), plus the waiting time before treatment starts — realistically, months of the year may pass untreated, with treatment concentrated in the remainder. Private: the monthly fee from month one, rising with dose escalation, totalling a four-figure sum for the year — but with all twelve months treated. The genuine comparison is therefore not "under £10 versus £2,000"; it is "a partially treated year at minimal cost versus a fully treated year at meaningful cost". Which of those is better value depends on how much the untreated months cost you in health, which only you and a clinician can weigh.

Eligibility edge cases

Some situations sit awkwardly between the routes. A BMI just under NHS thresholds but within the medicine's licence: private treatment is the realistic option. Qualifying but living in an area with thin service provision: technically eligible, practically private. Type 2 diabetes alongside obesity: the NHS diabetes route for Mounjaro may be faster than the weight-management route — ask your GP to check both doors. Previously treated privately and now NHS-eligible: transfer is possible, but continuity of dose and records needs managing deliberately.

It is also worth valuing your own time in the comparison. The NHS route involves appointments, referrals and chasing; the private route involves provider research and monthly logistics. Neither burden is trivial, and people in demanding jobs or caring roles sometimes find the private route's predictability is itself part of what they are paying for.

The economics of stopping and restarting

One cost dynamic deserves its own paragraph: interrupted treatment. Evidence across this class shows weight tends to return gradually after stopping, which means a stop-start pattern — treat for three months, stop for six, restart — is the worst value available: you pay repeatedly for early-phase titration months (the least effective ones) and forfeit the consolidation that makes the spend worthwhile. Whichever route you take, going in with a realistic duration and a maintenance plan protects both the health outcome and the money. This is also the honest argument against starting privately if the budget only stretches to a short trial.

Keeping private costs honest without cutting corners

The safe ways to spend less are unglamorous: choose an inclusive provider over a fee-stacking one; review doses with your prescriber rather than escalating by default, since the lowest effective dose is both good medicine and good economics; pause properly during breaks instead of letting a subscription run; and reassess honestly at review points — paying indefinitely for a treatment that has plateaued without a plan is the costliest pattern in this market. The unsafe way to spend less is unregulated sellers, which is not a saving but a different product entirely.

So which route is right for you?

If you clearly meet NHS criteria, your local services have capacity, and you can wait — take the NHS route; it is excellent value. If speed matters, your area's provision is limited, or you sit outside current NHS cohorts but within the medicine's licence, regulated private treatment is the legitimate alternative, priced as above. The only wrong answer is the unregulated one: websites supplying without consultation are not a third route, they are a hazard.

A free consultation with a UK-registered clinician can place you on this map in ten minutes: whether treatment is clinically appropriate, which medicine fits, and what it would actually cost you month to month. That conversation is the real starting line — the price comparison only matters once you know you are comparing options you are eligible for.